Nintedanib for patients with lymphangioleiomyomatosis: a phase 2, open-label, single-arm study

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(24)00217-0/abstract?utm_campaign=update-lanres&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanres&_hsenc=p2ANqtz-9rWUpx0v7hGMQVu3ugP1gSItqXQ5pI23S50v6wYpY1LX3xJF62fQON3AIpRb-nAH8z8IUhDxnbDVwkZ74zhWMjsUIGUA&_hsmi=338784243&utm_content=338419591&utm_source=hs_email